Ginkgo Bioworks Holdings, Inc. (DNA) insider details RSU vesting and tax sale

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. reported insider equity transactions by a senior officer. On 12/12/2025, restricted stock units vested and were converted into 1,174 and 312 shares of Class A common stock, reflecting ongoing equity compensation. After these conversions, the officer directly held 8,224 Class A shares.

On 12/15/2025, 736 Class A shares were sold at $8.886 per share to satisfy tax withholding obligations tied to the vesting of restricted stock and restricted stock units. The company’s equity incentive plans allow these mandatory “sell to cover” transactions, which are described as non‑discretionary for the officer. Following the sale, the officer directly owned 7,488 Class A shares and continued to hold restricted stock units subject to multi‑year vesting schedules beginning May 1, 2024.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coen Steven P.

(Last) (First) (Middle)

C/O GINKGO BIOWORKS HOLDINGS, INC.

27 DRYDOCK AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ginkgo Bioworks Holdings, Inc. [ DNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See remarks

3. Date of Earliest Transaction (Month/Day/Year)
12/12/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/12/2025		M(1)		1,174	A	(1)	7,912	D
Class A Common Stock	12/12/2025		M(1)		312	A	(1)	8,224	D
Class A Common Stock	12/15/2025		S(2)		736	D	$8.886	7,488	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/12/2025		M(1)			1,174	(3)	(3)	Class A Common Stock	1,174	(1)	9,992	D
Restricted Stock Units	(1)	12/12/2025		M(1)			312	(4)	(4)	Class A Common Stock	312	(1)	4,223	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.

2. Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.

3. The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.

4. The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.

Remarks:

Chief Financial Officer

	/s/ Karen Tepichin, Attorney-in-Fact	12/16/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction was reported at Ginkgo Bioworks (DNA)?

A senior officer of Ginkgo Bioworks Holdings, Inc. reported the vesting and conversion of restricted stock units into Class A common stock on 12/12/2025 and a subsequent sale of shares on 12/15/2025.

How many Ginkgo Bioworks (DNA) shares were acquired through RSU vesting?

On 12/12/2025, restricted stock units converted into 1,174 shares of Class A common stock in one grant and 312 shares in another grant, as part of the officer’s equity compensation.

How many Ginkgo Bioworks (DNA) shares were sold and at what price?

On 12/15/2025, the reporting officer sold 736 shares of Ginkgo Bioworks Class A common stock at a price of $8.886 per share.

Why were Ginkgo Bioworks (DNA) shares sold by the insider?

The filing states that 736 shares were sold to cover tax withholding obligations related to the vesting of restricted stock and restricted stock units, under the company’s equity incentive plans.

What is the insider’s Ginkgo Bioworks (DNA) share ownership after these transactions?

After the reported transactions, the officer directly owned 7,488 shares of Ginkgo Bioworks Class A common stock.

How do the Ginkgo Bioworks (DNA) restricted stock units vest for this officer?

One RSU grant vested 25% of its underlying shares on May 1, 2024, with the remainder vesting in 36 equal monthly installments. Another grant vested 2/48ths of its shares on May 1, 2024, with the remaining shares vesting in 46 equal monthly installments.

What position does the reporting person hold at Ginkgo Bioworks (DNA)?

The remarks section identifies the reporting person’s role as Chief Financial Officer of Ginkgo Bioworks Holdings, Inc.